PRIME/BOOST VACCINE USING ALVAC 1452 W/ RECOMBINANT GP160 IN HIV INFECTION

艾滋病毒感染的特点是在感染的所有阶段都有高水平的病毒复制。 病毒复制导致CD 4细胞破坏和更新水平增加，如果不加控制，则导致免疫缺陷、艾滋病和死亡。 这种发病机制的模式促使治疗模式发生了巨大的变化，从有症状的个体的晚期干预演变为“早打，重打”的策略。 治疗，虽然在许多方面非常有效，但昂贵，复杂，需要一丝不苟的依从性，即使在最好的情况下，也难以长期维持。 我们已经招募了HIV感染者参加各种临床试验，研究强化抗逆转录病毒方案的抗病毒活性和免疫效果。 我们的患者包括那些新感染的人;在感染后90天内接受治疗，以及慢性感染者。 对治疗的反应通常是有利的，几乎所有受试者都经历了活性病毒复制的长期抑制，外周血和组织中携带可检测到的HIV的细胞几乎完全消失。 这项临床试验旨在从我们正在进行的临床试验中选择HIV-1检出率最低的受试者。 我们计划通过在极轻微病毒血症的受试者中接种疫苗来增强HIV-1特异性免疫应答。 受试者将接受初免/加强疫苗方案，使用表达多种HIV抗原（包括env、gag、pol和nef）的金丝雀痘构建体作为初免，使用可溶性env蛋白作为加强。 将测量艾滋病毒特异性反应的诱导。

HIV infection is characterized by high levels of virus replication at all stages of infection. Virus replication causes increased levels of CD4 cell destruction and turnover, and when unchecked, immunodeficiency, AIDS and death. This model of pathogenesis has prompted a dramatic change in the treatment paradigm which has evolved from late intervention in symptomatic individuals to a "hit early, hit hard" strategy. Therapies, though highly effective in many, are costly, complex, and require meticulous compliance and even in the best of circumstances, are difficult to maintain over the long term. We have enrolled HIV-infected individuals in a variety of clinical trials investigating the antiviral activity and immunologic effect of intensive antiretroviral regimens. Our patients include those newly infected; presenting for treatment within 90 days of infection, as well as chronically infected individuals. The response to therapy has been generally favorable, with nearly all subjects experiencing prolonged suppression of active virus replication and near complete disappearance of cells harboring detectable HIV in peripheral blood and tissue. This clinical trial aims to select subjects from our ongoing clinical trials with minimal detectable HIV-1. We plan to boost HIV-1 specific immune responses through vaccination in subjects with minimal viremia. Subjects will be given a prime/boost vaccine regimen using a canary pox construct expressing multiple HIV antigens including env, gag, pol, and nef as a prime and a soluble env protein as a boost. The induction of HIV-specific responses will be measured.